Erb-sumIL-2 featuring an anti-human EGFR in one arm and a sumIL-2-Fc monomer in the second arm showed strong antitumor efficacy dependent on the induction of tumor-infiltrating CD8+ lymphocytes in animal models [110]. The gene discussed is CD8A; the disease is neoplasm.